vida: extract claims from 2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high

- Source: inbox/queue/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md

@@ -10,12 +10,16 @@ agent: vida
 scope: causal
 sourcer: The Lancet Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-related:
-- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
-reweave_edges:
-- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation|related|2026-04-12
+related: ["Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse", "cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions"]
+reweave_edges: ["Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation|related|2026-04-12"]
 ---
 
 # Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
 
-Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.
+Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.
+
+## Extending Evidence
+
+**Source:** Compass Pathways COMP005 Phase 3 trial (n=258)
+
+Psilocybin inverts the continuous treatment model by producing 26-week durability from a single 25mg dose in treatment-resistant depression (MADRS -3.6, p<0.001), with psychological support embedded as a required protocol component (preparation, monitored session, integration) rather than optional relapse mitigation. This represents a fundamentally different pharmacological paradigm from daily-dosing antidepressants.

domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md

@@ -10,12 +10,17 @@ agent: vida
 scope: causal
 sourcer: Shiels MS, Chernyavskiy P, Anderson WF, et al. (NCI)
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
-supports:
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
-reweave_edges:
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
+supports: ["Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation"]
+reweave_edges: ["Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07"]
+related: ["cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths", "cvd-stagnation-reversed-racial-health-convergence-by-stopping-black-mortality-improvements", "midlife-cvd-mortality-increased-in-many-us-states-after-2010-representing-reversal-not-stagnation"]
 ---
 
 # CVD mortality stagnation drives US life expectancy plateau 3-11x more than drug deaths inverting the dominant opioid crisis narrative
 
-NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 years in men. This creates a ratio where CVD stagnation effect is approximately 3-11x larger than drug mortality effect. The authors concluded that stagnating decline in CVD mortality was 'the main culprit outpacing and overshadowing the effects of all other causes of death.' This directly contradicts the dominant public narrative attributing US mortality stagnation primarily to the opioid epidemic. The finding is particularly significant because CVD/metabolic decline is structural and not easily reversible like epidemic-driven mortality, suggesting the life expectancy plateau represents a deeper health system failure than crisis-driven explanations imply. This mechanism was visible in 2020 data and has been confirmed by subsequent 2025-2026 literature including cohort-level analysis showing a distinct 2010 period effect.
+NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 years in men. This creates a ratio where CVD stagnation effect is approximately 3-11x larger than drug mortality effect. The authors concluded that stagnating decline in CVD mortality was 'the main culprit outpacing and overshadowing the effects of all other causes of death.' This directly contradicts the dominant public narrative attributing US mortality stagnation primarily to the opioid epidemic. The finding is particularly significant because CVD/metabolic decline is structural and not easily reversible like epidemic-driven mortality, suggesting the life expectancy plateau represents a deeper health system failure than crisis-driven explanations imply. This mechanism was visible in 2020 data and has been confirmed by subsequent 2025-2026 literature including cohort-level analysis showing a distinct 2010 period effect.
+
+## Extending Evidence
+
+**Source:** CDC NCHS Data Brief 548, January 2026
+
+The 2024 life expectancy improvement was driven by both declining drug deaths (-26.2%) AND declining heart disease mortality, suggesting CVD improvements contributed alongside overdose reductions. This complicates the '3-11x more important' framing, as both acute and chronic causes moved favorably in 2024.

domains/health/psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: COMP005 trial demonstrates MADRS -3.6 point improvement (p<0.001) with benefits maintained through 26 weeks from a single 25mg dose, marking the first psychedelic to reach Phase 3 efficacy threshold
+confidence: experimental
+source: Compass Pathways COMP005 Phase 3 trial (n=258, 32 US sites)
+created: 2026-05-10
+title: Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
+agent: vida
+sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
+scope: causal
+sourcer: Compass Pathways
+challenges: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse"]
+---
+
+# Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
+
+The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.

domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: COMP005 trial protocol mandated preparation sessions, monitored dosing sessions, and post-session integration as required elements, indicating psilocybin efficacy depends on both pharmacological mechanism and structured psychological process
+confidence: experimental
+source: Compass Pathways COMP005 Phase 3 protocol design
+created: 2026-05-10
+title: Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
+agent: vida
+sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
+scope: structural
+sourcer: Compass Pathways
+supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+---
+
+# Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
+
+The COMP005 trial embedded psychological support as a mandatory protocol component across three phases: pre-session preparation, monitored dosing session (with trained facilitators present throughout the 6-8 hour experience), and post-session integration sessions. This design choice indicates that psilocybin therapy is not purely pharmacological but rather a hybrid intervention where the drug enables a psychological process that requires professional support to translate into clinical benefit. The trial's positive results cannot be attributed to the molecule alone but rather to the complete protocol package. This has significant implications for clinical implementation: psilocybin therapy will require specialized training infrastructure, dedicated session spaces, and multi-hour clinician time per patient—creating a fundamentally different delivery model than traditional psychiatric pharmacotherapy. The psychological support requirement also creates a natural quality control mechanism that may prevent the commoditization pathway seen with other psychiatric medications. This sits at the clinical/non-clinical interface: the pharmacological mechanism (5-HT2A agonism, neuroplasticity) is necessary but not sufficient; the psychological meaning-making process enabled by the drug state appears essential for durable benefit. The FDA approval pathway will need to specify not just the molecule but the complete therapeutic protocol, creating precedent for regulating hybrid pharmacological-psychological interventions.

domains/health/us-life-expectancy-2024-recovery-reflects-acute-mortality-improvement-not-structural-reversal.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "The 2024 life expectancy record (79.0 years) was driven by a 26.2% decline in drug overdoses and reduced unintentional injury deaths, but obesity remains at 40.3% and IHME projects US falling to 66th globally by 2050 due to chronic metabolic disease"
+confidence: likely
+source: CDC NCHS Data Brief 548 and 549, January 2026
+created: 2026-05-10
+title: US life expectancy recovery to all-time high in 2024 reflects acute mortality improvement that leaves structural metabolic threats intact
+agent: vida
+sourced_from: health/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md
+scope: structural
+sourcer: CDC NCHS
+supports: ["us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains"]
+challenges: ["americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s"]
+related: ["americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s", "us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths"]
+---
+
+# US life expectancy recovery to all-time high in 2024 reflects acute mortality improvement that leaves structural metabolic threats intact
+
+CDC NCHS reports US life expectancy reached an all-time high of 79.0 years in 2024, surpassing the pre-COVID 2019 level of 78.8 years. The primary driver was a 26.2% year-over-year decline in drug overdose deaths (from 31.3 to 23.1 per 100K), with synthetic opioid deaths falling 35.6%. This represents the largest single-year improvement in US drug overdose history. However, this acute mortality improvement does not address the structural metabolic disease burden that drives long-term projections. Obesity prevalence remains at 40.3% nationally, and IHME forecasts project the US falling from current rankings to 66th globally in life expectancy by 2050 due to compounding metabolic disease. The 2024 recovery demonstrates that the 'deaths of despair' crisis (2017-2022) was partially cyclical and responsive to intervention (naloxone distribution, fentanyl supply disruption, treatment expansion), but the underlying structural determinants identified in existing KB claims—economic restructuring, social isolation, ultra-processed food environments—remain unaddressed. The improvement in acute causes (overdoses, homicides) coexists with persistent chronic disease trajectories that will dominate future mortality patterns.

domains/health/us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains.md

@@ -23,3 +23,10 @@ The structural threats offsetting these gains are obesity and drug mortality. IH
 This forecast provides critical context for the 2024 CDC life expectancy all-time high of 79.0 years. The IHME model treats the 2024 improvement as partially cyclical (COVID dissipation plus fentanyl supply disruption) rather than structural resolution. The divergence between acute mortality improvement (CDC 2024) and structural disease burden trajectory (IHME 2050) suggests the binding constraints on US healthspan remain obesity-driven metabolic disease and socioeconomic drivers of drug mortality, even as acute cardiovascular care improves.
 
 The global ranking decline is particularly revealing: it indicates the US is not declining absolutely but failing to address structural risk factors as effectively as peer nations. The 2050 projection assumes current policy trajectories continue—it does not account for potential GLP-1 scale effects, major policy reforms, or fentanyl supply dynamics that could alter the trajectory.
+
+
+## Supporting Evidence
+
+**Source:** CDC NCHS Data Brief 548 and 549, January 2026
+
+The 2024 life expectancy recovery to 79.0 years was driven by acute mortality improvements (drug overdoses -26.2%, unintentional injuries -14%, homicides declining), validating the 'drug mortality offset' mechanism. However, obesity prevalence remains at 40.3% and chronic metabolic disease trajectories are unchanged, supporting the projection that structural metabolic threats will dominate post-2024 mortality patterns.

entities/health/comp005-trial.md

@@ -0,0 +1,54 @@
+# COMP005 Phase 3 Trial
+
+**Sponsor:** Compass Pathways  
+**Intervention:** COMP360 psilocybin 25mg single dose  
+**Indication:** Treatment-resistant depression  
+**Status:** Completed, positive primary endpoint  
+**Reported:** June 23, 2025  
+
+## Trial Design
+
+- **Phase:** 3
+- **Design:** Randomized, double-blind, placebo-controlled
+- **Sample Size:** n=258
+- **Sites:** 32 sites in the United States
+- **Population:** Treatment-resistant depression (≥2 failed antidepressant courses)
+- **Intervention:** Single dose COMP360 25mg vs. placebo
+- **Protocol:** Embedded psychological support (preparation, monitored session, integration)
+
+## Primary Endpoint
+
+**MADRS change from baseline at Week 6:**
+- Treatment difference: **-3.6 points** (95% CI [-5.7, -1.5])
+- **p<0.001** (highly statistically significant)
+
+## Secondary Outcomes
+
+- **Response Rate:** 25% achieved clinically meaningful MADRS reduction (≥25%) at week 6
+- **Durability:** Improvement maintained through 26-week follow-up after single dose
+- **Rapid Onset:** Statistically significant benefit from next day after dosing
+
+## Safety Profile
+
+- All treatment-emergent adverse events: mild or moderate severity
+- Most adverse events resolved within 24 hours
+- Frequently reported: headache, nausea, anxiety, visual hallucination
+- No clinically meaningful imbalance in suicidal ideation between arms
+- No unexpected safety findings
+
+## Historical Significance
+
+- **First investigational psychedelic to report positive Phase 3 efficacy data**
+- First classic psychedelic to reach Phase 3 evidence level
+- Establishes proof-of-concept for FDA approval pathway for psychedelic therapeutics
+
+## Clinical Context
+
+- Effect size (-3.6 MADRS points) comparable to existing TRD augmentation strategies (2-4 points)
+- Single-dose 26-week durability represents paradigm shift from daily-dosing chronic treatment model
+- Psychological support protocol is mandatory component, not optional adjunct
+- Treatment-resistant depression population: ~7M Americans who have failed 2+ antidepressant courses
+
+## Timeline
+
+- **2025-06-23** — Primary endpoint results announced: MADRS -3.6 (p<0.001), first positive Phase 3 data for any psychedelic

entities/health/compass-pathways.md

@@ -0,0 +1,44 @@
+# Compass Pathways
+
+**Type:** Clinical-stage biopharmaceutical company  
+**Focus:** Mental health, psychedelic therapeutics  
+**Headquarters:** United Kingdom  
+**Lead Asset:** COMP360 (synthetic psilocybin)  
+
+## Overview
+
+Compass Pathways is a clinical-stage biopharmaceutical company developing COMP360, a proprietary synthetic psilocybin formulation for treatment-resistant depression and other mental health conditions. The company holds FDA Breakthrough Therapy Designation and reported the first positive Phase 3 efficacy data for any investigational psychedelic in June 2025.
+
+## Key Programs
+
+### COMP360 Psilocybin
+- **Indication:** Treatment-resistant depression (TRD)
+- **Mechanism:** 5-HT2A receptor agonism with embedded psychological support protocol
+- **Status:** Phase 3 (COMP005 positive, COMP006 pending)
+- **Regulatory:** FDA Breakthrough Therapy Designation, Commissioner National Priority Voucher (April 2026)
+
+## Clinical Evidence
+
+### COMP005 Phase 3 Trial
+- **Design:** Randomized, double-blind, placebo-controlled (n=258, 32 US sites)
+- **Population:** Treatment-resistant depression (≥2 failed antidepressant courses)
+- **Intervention:** Single dose COMP360 25mg vs. placebo with psychological support protocol
+- **Primary Endpoint:** MADRS change at Week 6: -3.6 points (95% CI [-5.7, -1.5], p<0.001)
+- **Durability:** Benefits maintained through 26-week follow-up from single dose
+- **Safety:** All adverse events mild-to-moderate, resolved within 24 hours
+
+## Regulatory Pathway
+
+- **NDA Filing:** Expected Q4 2026 (pending COMP006 26-week data)
+- **Breakthrough Designation:** Held for multiple years
+- **Priority Voucher:** Received April 24, 2026
+
+## Significance
+
+COMP005 represents the first Phase 3 evidence for a psychedelic drug and the first classic psychedelic to reach Phase 3 efficacy threshold, establishing proof-of-concept for FDA approval of the broader class.
+
+## Timeline
+
+- **2025-06-23** — COMP005 Phase 3 trial achieves primary endpoint with MADRS -3.6 point improvement (p<0.001), marking first positive Phase 3 data for any investigational psychedelic
+- **2026-04-24** — Receives Commissioner National Priority Voucher
+- **2026-Q4** — NDA filing expected (pending COMP006 data)

inbox/archive/health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md

@@ -7,10 +7,13 @@ date: 2025-06-23
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: high
 tags: [psilocybin, treatment-resistant-depression, Phase-3, clinical-trial, mental-health, psychedelic-therapy, FDA, Compass-Pathways]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md

@@ -7,10 +7,13 @@ date: 2026-01-29
 domain: health
 secondary_domains: []
 format: government-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: high
 tags: [life-expectancy, deaths-of-despair, drug-overdose, mortality, epidemiology, population-health, CDC, NCHS]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/null-result/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md

@@ -7,10 +7,11 @@ date: 2026-02-17
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: null-result
 priority: high
 tags: [psilocybin, treatment-resistant-depression, Phase-3, clinical-trial, mental-health, psychedelic-therapy, FDA, NDA, Compass-Pathways]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content